Sean P. Nolan - 20 May 2021 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role: Director
Signature: /s/ Kamran Alam, Attorney-in-Fact
Issuer symbol: TSHA
Transactions as of: 20 May 2021
Transactions value $: $26,150
Form type: 4
Filing time: 24 May 2021, 08:39:46
Next filing: 27 May 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TSHA	Common Stock	Purchase	$26.1K	+1.17K		$22.35^*	1.17K	20 May 2021	Direct	F1
holding	TSHA	Common Stock						1.09M	20 May 2021	See Footnote	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.04 to $22.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2	The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of the LLC and has shared voting and investment power with respect to the shares held by the LLC.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.04 to $22.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of the LLC and has shared voting and investment power with respect to the shares held by the LLC.